Some drugs that can be administered despite low eGFR values are marred by side effects such as hypoglycemia with repaglinide, volume retention and risk of distal fractures with pioglitazone, or may impact negatively on CKD progression (e.g., dipeptidyl peptidase 4 inhibitors). Here, DPP4 is linked to chronic kidney disease.